Hisco announced on August 7 that the company's HSK47388 tablets have recently been approved for clinical trials. HSK47388 tablets are oral, potent, and highly selective drugs independently developed by the company. They are intended for the treatment of autoimmune diseases. Innovative drugs have a long development cycle, many steps, and high risks, and are easily affected by uncertainties.

Zhitongcaijing · 08/07/2025 10:09
Hisco announced on August 7 that the company's HSK47388 tablets have recently been approved for clinical trials. HSK47388 tablets are oral, potent, and highly selective drugs independently developed by the company. They are intended for the treatment of autoimmune diseases. Innovative drugs have a long development cycle, many steps, and high risks, and are easily affected by uncertainties.